Optina Diagnostics is a medtech company that is working on a hyperspectral camera to image the retina over a vast array of neighbouring light wavelengths at a very high speed. These hyperspectral retinal images are combined with artificial intelligence to accurately identify a range of ocular and neurological pathologies, including Alzheimer’s disease.
CRVI’s team of experts and researchers explored and developed several types of deep neural networks (DNNs) to help Optina Diagnostics improve their artificial intelligence (AI) algorithms to optimize early detection of Alzheimer’s using the beta-amyloid protein. They also supported Optina Diagnostics in their search for public funding.
